Breaking News Instant updates and real-time market news.

AMGN

Amgen

$162.42

-1.69 (-1.03%)

09:01
06/19/17
06/19
09:01
06/19/17
09:01

Amgen: FDA accepts sBLA to expand indication for XGEVA

Amgen announced that the U.S. FDA has accepted the XGEVA supplemental Biologics License Application that seeks to expand the currently approved indication for the prevention of fractures and other skeletal-related events in patients with bone metastases from solid tumors to include patients with multiple myeloma. The FDA has set a Prescription Drug User Fee Act action date of Feb. 3, 2018.

  • 19

    Jul

  • 14

    Aug

AMGN Amgen
$162.42

-1.69 (-1.03%)

06/12/17
LEER
06/12/17
NO CHANGE
Target $161
LEER
Market Perform
Amgen price target raised to $161 on Neulasta biosimilar delay at Leerink
Leerink analyst Geoffrey Porges noted that Coherus Biosciences (CHRS) received a complete response letter from the FDA for its biosimilar to Amgen's (AMGN) Neulasta, which he views as likely delaying its launch by at least a year. However, the "windfall" is offset by the Supreme Court decision that "effectively eliminates" the 6-month delay for biosimilars associated with notification, Porges tells investors. Based on his forecast for a six-month delay in the timing of a Neulasta biosimilar launch in the U.S., to the second quarter of 2018 from the fourth quarter of 2017, Porges increased his 2018 Amgen revenue forecast by $500M and raised his price target to $161 from $159, though he keeps a Market Perform rating on the stock.
05/22/17
ADAM
05/22/17
NO CHANGE
Target $85
ADAM
Buy
CV events 'may kill' Amgen's romosozumab development, says Canaccord
Canaccord analyst John Newman said Amgen (AMGN) and partner UCB's report of a higher rate of cardiovascular Serious Adverse Events for romosozumab in the Phase 3 ARCH study in osteoporosis suggests a much lower chance of FDA approval for the drug and may "kill" romosozumab's development. He notes that Merck's (MRK) cathepsin-K inhibitor was previously discontinued due to increased risk of atrial fibrillation and stroke. In addition to the safety signals, Newman points out that romosozumab was worse than Radius' (RDUS) Tymlos for non-vertebral fracture and for vertebral fracture, suggesting Radius' drug also has much better efficacy, said the analyst, who keeps a Buy rating and $85 price target on Radius Health shares, which are up $4.47, or 12.8%, to $39.40 in pre-market trading.
05/22/17
LEER
05/22/17
NO CHANGE
Target $159
LEER
Market Perform
Leerink sees only 50/50 chance of Amgen's Evenity hitting market
After Amgen (AMGN) and UCB reported an "imbalance of positively adjudicated serious cardiovascular adverse events" in its Phase 3 study of Evenity, Leerink analyst Geoffrey Porges believes the product now has only a 50/50 probability of coming to market at all. The analyst lowered his price target for Amgen shares to $159 from $160 and keeps a Market Perform rating on the name. Radius Health (RDUS), which has a drug that would compete with Evenity, is trading up 16% to $40.58 in the premarket.
05/22/17
FBCO
05/22/17
NO CHANGE
Target $177
FBCO
Neutral
Amgen romosozumab U.S. approval in July 'off the table,' says Credit Suisse
After Amgen (AMGN) and UCB (UCBJY) announced that the Evenity "ARCH" study met both primary endpoints but that there was also a newly observed cardiovascular safety signal in the trial, Credit Suisse analyst Alethia Young said any potential U.S. approval by the drug's July 19 PDUFA date is "off the table" and it is unclear as of now what U.S. approval timelines may be. She reduced her probability of success for romosozumab to 80% from 100% and lowered her price target on Amgen to $177 from $178. Young keeps a Neutral rating on Amgen shares.

TODAY'S FREE FLY STORIES

LEG

Leggett & Platt

$48.15

-0.21 (-0.43%)

14:20
01/19/18
01/19
14:20
01/19/18
14:20
Options
Put buying in Leggett and Platt »

Put buying in Leggett and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:20
01/19/18
01/19
14:20
01/19/18
14:20
General news
Fedspeak will be truncated next week »

Fedspeak will be…

$NSD

NASDAQ Market Internals

14:17
01/19/18
01/19
14:17
01/19/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
01/19/18
01/19
14:16
01/19/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$179.80

2.2 (1.24%)

, AMZN

Amazon.com

$1,293.32

-1.68 (-0.13%)

14:08
01/19/18
01/19
14:08
01/19/18
14:08
Periodicals
Facebook not bidding for Thursday Night Football rights, Bloomberg reports »

Facebook (FB) has decided…

FB

Facebook

$179.80

2.2 (1.24%)

AMZN

Amazon.com

$1,293.32

-1.68 (-0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 23

    Jan

  • 31

    Jan

  • 01

    Feb

  • 07

    Feb

  • 28

    Feb

  • 18

    Mar

HPQ

HP Inc.

$23.62

0.33 (1.42%)

14:06
01/19/18
01/19
14:06
01/19/18
14:06
Conference/Events
HP Inc. to hold a webcast »

Global Head of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 22

    Jan

RENN

Renren

$10.96

-0.16 (-1.44%)

14:05
01/19/18
01/19
14:05
01/19/18
14:05
Options
Renren call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNXP

Tonix Pharmaceuticals

$3.66

0.03 (0.83%)

14:04
01/19/18
01/19
14:04
01/19/18
14:04
Hot Stocks
Tonix: Horsepox virus showed protection vs. lethal vaccinia infection in study »

Tonix Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLK

BlackRock

$587.11

7.89 (1.36%)

, CIR

Circor

$53.40

1.12 (2.14%)

14:04
01/19/18
01/19
14:04
01/19/18
14:04
Hot Stocks
BlackRock reports 12.6% passive stake in Circor »

In a regulatory filing,…

BLK

BlackRock

$587.11

7.89 (1.36%)

CIR

Circor

$53.40

1.12 (2.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 22

    Feb

VIA

Viacom

$39.70

1.85 (4.89%)

, FOXA

21st Century Fox

$36.18

-0.93 (-2.51%)

14:04
01/19/18
01/19
14:04
01/19/18
14:04
Hot Stocks
Box Office Battle: 'Jumanji,' 'The Post' expected to hold off '12 Strong' »

Still expected to remain…

VIA

Viacom

$39.70

1.85 (4.89%)

FOXA

21st Century Fox

$36.18

-0.93 (-2.51%)

LGF.B

Lionsgate

$33.25

0.41 (1.25%)

VIAB

Viacom

$33.95

1.99 (6.23%)

CMCSA

Comcast

$41.85

0.17 (0.41%)

CMCSK

Comcast

LGF.A

Lionsgate

$35.22

0.72 (2.09%)

TWX

Time Warner

$92.90

-0.07 (-0.08%)

DIS

Disney

$110.18

-0.24 (-0.22%)

SNE

Sony

$49.80

0.63 (1.28%)

FOX

21st Century Fox

$35.73

-0.76 (-2.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 06

    Feb

  • 07

    Feb

  • 07

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

BLK

BlackRock

$586.98

7.76 (1.34%)

, BXS

BancorpSouth

$34.90

0.35 (1.01%)

14:02
01/19/18
01/19
14:02
01/19/18
14:02
Hot Stocks
BlackRock reports 10.2% passive stake in BancorpSouth »

In a regulatory filing,…

BLK

BlackRock

$586.98

7.76 (1.34%)

BXS

BancorpSouth

$34.90

0.35 (1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 25

    Jan

14:00
01/19/18
01/19
14:00
01/19/18
14:00
General news
Action Economics Survey results: »

Action Economics Survey…

BASFY

BASF

$29.54

0.825 (2.87%)

, BAYRY

Bayer

$31.82

0.015 (0.05%)

13:57
01/19/18
01/19
13:57
01/19/18
13:57
Periodicals
Breaking Periodicals news story on BASF, Bayer »

Capitol Forum says BASF,…

BASFY

BASF

$29.54

0.825 (2.87%)

BAYRY

Bayer

$31.82

0.015 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

  • 25

    Mar

13:55
01/19/18
01/19
13:55
01/19/18
13:55
General news
SF Fed moderate Williams said economic tailwinds »

SF Fed moderate Williams…

OCPNY

Olympus Corp

$38.27

-0.12 (-0.31%)

13:54
01/19/18
01/19
13:54
01/19/18
13:54
Hot Stocks
Judge grants new trial for Bigler Family vs. Olympus wrongful-death case »

A King County court has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

C

Citi

$77.99

0.6 (0.78%)

13:52
01/19/18
01/19
13:52
01/19/18
13:52
Periodicals
Citi plans to have post-Brexit trading hub running by year end, Bloomberg says »

Citigroup intends to have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 24

    Jan

CANF

Can-Fite BioPharma

$1.76

0.01 (0.57%)

13:50
01/19/18
01/19
13:50
01/19/18
13:50
Conference/Events
Can-Fite BioPharma participates in lunch meeting with Philadelphia Securities »

Luncheon Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

13:50
01/19/18
01/19
13:50
01/19/18
13:50
Options
VIX slips on a relatively quiet monthly expiration »

VIX slips on a relatively…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:50
01/19/18
01/19
13:50
01/19/18
13:50
General news
Oil Action: Baker-Hughes »

Oil Action: Baker-Hughes…

KMI

Kinder Morgan

$18.97

-0.045 (-0.24%)

13:45
01/19/18
01/19
13:45
01/19/18
13:45
Options
Post earnings premium seller collects $13M in KinderMorgan »

Post earnings premium…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$91.92

1.61 (1.78%)

13:45
01/19/18
01/19
13:45
01/19/18
13:45
Options
Incyte call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

PRQR

ProQR Therapeutics

13:31
01/19/18
01/19
13:31
01/19/18
13:31
Conference/Events
ProQR Therapeutics to h old an investor event »

Investor Event will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

CMC

Commercial Metals

$24.83

-0.26 (-1.04%)

13:30
01/19/18
01/19
13:30
01/19/18
13:30
Options
Second day of call buying in Commercial Metals »

Second day of call buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLEX

Flex

$19.61

0.17 (0.87%)

13:25
01/19/18
01/19
13:25
01/19/18
13:25
Options
Flex call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

CSCO

Cisco

$41.30

0.1 (0.24%)

13:22
01/19/18
01/19
13:22
01/19/18
13:22
Periodicals
Cisco expands Spectre, Meltdown investigation to nine more products, CRN reports »

Cisco added nine more…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.